Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira® in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity
Dongyang Li, Yuhuan Jiao, Kun Wu, Hongyun Ma, Qianqian Hong, Liangzhi Xie. Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira® in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity. // Current Therapeutic Research. – 2026. – DOI: 10.1016/j.curtheres.2026.100848. – URL: https://doi.org/10.1016/j.curtheres.2026.100848
Dongyang Li, Yuhuan Jiao, Kun Wu, Hongyun Ma, Qianqian Hong, & Liangzhi Xie (2026). Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira® in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity. Current Therapeutic Research. https://doi.org/10.1016/j.curtheres.2026.100848
Dongyang Li, et al. “Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira® in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity.” Current Therapeutic Research, 2026. doi:10.1016/j.curtheres.2026.100848.
@article{Li2026,
title = {Population pharmacokinetic modeling of adalimumab biosimilar SCT630 and Humira® in healthy participants and patients with moderate to severe plaque psoriasis to establish PK similarity},
author = {Li, Dongyang and Jiao, Yuhuan and Wu, Kun and Ma, Hongyun and Hong, Qianqian and Xie, Liangzhi},
journal = {Current Therapeutic Research},
year = {2026},
doi = {10.1016/j.curtheres.2026.100848},
url = {https://doi.org/10.1016/j.curtheres.2026.100848}
}